%0 Journal Article
%T Los valores persistentemente positivos de anticuerpos antifosfolip¨ªdicos est¨¢n relacionados con la aparici¨®n de trombosis durante el seguimiento de pacientes con s¨ªndrome antifosfolip¨ªdico Persistenly positive antiphospholipid antibodies are related with the appearance of thrombosis during follow-up with antiphospholipid syndrome
%A Gerardo Quintana L
%A Gerard Espinosa
%A Silvia Bucciarelli
%A Dolors T¨¢ssies
%J Revista Colombiana de Reumatolog¨ªa
%D 2007
%I Asociaci¨®n Colombiana de Reumatolog¨ªa
%X Objetivo: determinar si la presencia de valores persistentemente positivos de anticuerpos antifosfolip¨ªdicos (AAF) est¨¢ relacionada con trombosis recurrente en el seguimiento de pacientes con s¨ªndrome antifosfolip¨ªdico (SAF). M¨¦todos: se analizaron 141 pacientes con SAF (criterios de Sapporo). Los valores de anticoagulante l¨²pico (AL) y anticuerpos anticardiolipina (AAC) fueron definidos como persistentemente positivos cuando m¨¢s del 75% de las determinaciones fueron positivas durante el seguimiento (los AAF fueron medidos en cinco o m¨¢s ocasiones). La trombosis en el seguimiento fue definida como una trombosis recurrente en pacientes con episodios tromb¨®ticos previos o nuevos episodios en aquellos pacientes con p¨¦rdidas fetales previas. Resultados: ochenta y nueve pacientes presentaban SAF primario, 34 asociado a lupus eritema-toso sist¨¦mico (LES), 14 con s¨ªndrome similar al lupus, 3 con s¨ªndrome de Sjogren y 1 con enfermedad de BehObjective: to determine if the presence of persistently positive val¨²es of antiphospholipid (aPL) antibodies is related with recurrent thrombosis in the follow-up of pat¨ªent with antiphospholipid syndrome (APS). Patients and Methods: 141 patients with APS (Sapporo's criteria) were analyzed. Lupus antico-agulant (LAC) val¨²es and anticardiolipin antibodies (aCL) were defined as persistently positive when more than 75% of determinations were positive during the follow-up (aPL were measured on 5 or more occasions). Thrombosis in the follow-up was defined as a recurrent thrombosis in patient with previous thrombotic events or new events in those patients with previous fetal losses. Results: 89 patients suffered from primary APS, 34 associated to systemic lupus erythematosus (SLE), 14 to SLE-like, 3 to Sjogren's syndrome, and 1 to Behcet's disease. 56% liad a history of thrombosis, 29% of fetal losses, and 15% both thrombosis and fetal losses. Median time of follow-up and between the diagnosis and the last aPL determination was 68 months and 65 months (9-180), respectively. Median of determinations by patient was 8 (5-27). 31 patients suffered from thrombosis in the follow-up, 28 of them in form of recurrent thrombosis. 58 (41%) patients liad persistently positive aPL during follow-up, thus: 23 (39,65%) aCL IgG y LAC, 12 (20,7%) LAC, 8 (13,8%) aCL IgG, 5 (8,6%) aCL IgM, aCL IgG y LAC, 4 (6,9%) aCL IgM, 3 (5,1%) aCL IgG y aCL IgM y 3 (5,1%) aCL IgM y LAC, respectively. Risk for recurrent thrombosis during follow-up was increased in persistently positive aPL patients (OR 3,53; 95% CI 1,53-8,16; p=0,003) compared with transiently pos
%K s¨ªndrome antifosfolip¨ªdico
%K anticuerpos antifosfolip¨ªdico
%K anticoagulante l¨²pico
%K anticardiolipina
%K trombosis recurrente
%K antiphospholipid syndrome
%K antiphospholipid antibodies
%K lupus anticoagulant
%K anticardiolipin
%K recurrent thrombosis
%U http://www.scielo.org.co/scielo.php?script=sci_arttext&pid=S0121-81232007000400002